
CLAIMS

Claim 1: A compound of Formula (A):



(A),

or a tautomer, or a pharmaceutically acceptable salt of any of the foregoing,

wherein

R^1 is -OH;

R^2 is -C(O)H;

R^3 is C_1-C_6alkoxy or halogen;

G_1 and G_2 are each CH;

◯ indicates that the ring is aromatic;

Y^1 is C or N;

Y^2 is CH, N, NH, S, or O;

Y^3 is C or N;











Y^4 is CH, N, NH, S, or O;

Y^5 is CR^7, N, NH, S, or O;

wherein no more than one of Y^1, Y^2, Y^3, Y^4, and Y^5 is S or O and no more than four of Y^1, Y^2, Y^3, Y^4, and Y^5 are N or NH;

R^7 is H or C_1-C_6alkyl;

n is 0, 1, 2, or 3;

R^4 is ; wherein  is selected from the group consisting of , , , , , , , , , , , , , , , and ;

~~ indicates that the ring is saturated, partially unsaturated, or fully unsaturated;~~



~~G_3 is $CH(X_1\text{-}R^{6a})$, $C(X_1\text{-}R^{6a})$, N, $N(X_1\text{-}R^{6a})$, S, or O;~~

~~G_4 is $CH(X_2\text{-}R^{6b})$, $C(X_2\text{-}R^{6b})$, N, $N(X_2\text{-}R^{6b})$, S, or O;~~

~~G_5 is $CH(X_3\text{-}R^{6c})$, $C(X_3\text{-}R^{6c})$, N, $N(X_3\text{-}R^{6c})$, S, or O;~~

~~G_6 is $CH(X_4\text{-}R^{6d})$, $C(X_4\text{-}R^{6d})$, N, $N(X_4\text{-}R^{6d})$, S, or O; and~~

~~G_7 is N, C, or CH;~~

~~X_1, X_2, X_3, and X_4 are each independently absent,~~  ~~, or~~  ~~;~~

~~m is 1-6;~~

R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, $-NR^pR^q$, aryl, heterocyclyl, heteroaryl, -C_1-C_6alkyl-heterocyclyl, -OC(O)-heterocyclyl, $-C(O)R^h$, $-S(O)_2NR^{w1}R^{w2}$, $-S(O)_2R^y$, or $-NR^{z1}S(O)_2R^{z2}$, wherein the C_1-C_6alkyl and C_1-C_6alkoxy of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of cycloalkyl and halogen;

the aryl and heteroaryl of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, C_3-C_8cycloalkyl, -OH, and C_1-C_6alkyl-OH; and the heterocyclyl, -C_1-C_6alkyl-heterocyclyl, and -OC(O)-heterocyclyl of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently unsubstituted or substituted with one or more groups selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, C_1-C_6alkyl-OH, =O, and =S;

each R^h is independently selected from the group consisting of H, C_1-C_6alkyl, C_1-C_6alkoxy, and C_3-C_8cycloalkyl, and -NR^rR^s;

each R^p is independently H or C_1-C_6alkyl;

each R^q is independently C_2-C_3alkyl, -$C(O)R^t$, -$C(O)OR^u$, or -$C(O)NR^v$;


each R^r, R^s, R^{w1}, and R^{z1} is independently selected from H and C_1-C_6alkyl; and


each R^t, R^u, R^v, R^{w2}, R^y, and R^{z2} is independently selected from H, C_1-C_6alkyl, unsubstituted or substituted C_3-C_8cycloalkyl, and unsubstituted or substituted heterocyclyl~~;~~

~~or~~

~~G_5 is $CH(X_3\text{-}R^{6e})$ or $C(X_3\text{-}R^{6e})$, G_6 is $CH(X_4\text{-}R^{6d})$ or $C(X_4\text{-}R^{6d})$, and R^{6e} and R^{6d} are taken together with the carbon atoms to which they are attached to form a 6-membered aryl, a 6-membered heterocyclyl, or a 6-membered heteroaryl ring; wherein the 6-membered aryl, 6-membered heterocyclyl, and 6-membered heteroaryl rings are each independently unsubstituted or substituted~~.


Claim 2: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is selected from the group consisting of -OCH_3, Cl, and F.

Claim 3: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein  is selected from the group consisting of





Claim 4: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 0.



Claim 5: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein







is ; and

R^{6a}, R^{6b}, R^{6c}, and R^{6d} are each independently selected from the group consisting of hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, and 5- to 10-membered heteroaryl.

~~G_3 is $C(X_1\text{-}R^{6a})$; X_1 is absent,~~  ~~, or~~  ~~; m is 1-6; R^{6a} is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl;~~

~~G_4 is $C(X_2\text{-}R^{6b})$ or N; X_2 is absent,~~  ~~, or~~  ~~; m is 1-6; and R^{6b} is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl;~~















~~G_5 is $C(X_3\text{-}R^{6e})$; X_3 is absent,~~  ~~, or~~  ~~; m is 1-6; and R^{6e} is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl;~~


~~G_6 is $C(X_4\text{-}R^{6d})$; X_4 is absent,~~  ~~, or~~  ~~; m is 1-6; and R^{6d} is hydrogen, C_1-C_6alkyl, C_1-C_6haloalkyl, halo, C_6-C_{12} aryl, 3- to 10-membered heterocyclyl, or 5- to 10-membered heteroaryl; and~~











~~G_7 is C.~~











Claim 6: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one or more of R^{6a}, R^{6b}, R^{6c}, and R^{6d} are independently selected from the group consisting of C_1-C_6alkyl, C_1-C_6alkoxy, halo, -OH, $-NR^pR^q$, aryl, heterocyclyl, heteroaryl, -C_1-C_6alkyl-heterocyclyl, -OC(O)-heterocyclyl, $-C(O)R^h$, $-S(O)_2NR^{w1}R^{w2}$, $-S(O)_2R^y$, and $-NR^{z1}S(O)_2R^{z2}$.













Claim 7: The compound of claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is









































F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
N
,

F
HO
OHC
N
S
,

F
HO
OHC
N
S
,


F
HO
OHC
N
S
,

F
HO
OHC
N
O
N
,

F
HO
OHC
N
O
N
,

F
HO
OHC
N
S
N
,

F
HO
OHC
N
S
N
,

F
HO
OHC
N
N
S
,

F
HO
OHC
N
N
S
,

F
HO
OHC
N
N
O
N
,

F
HO
OHC
N
N
O
N
,

F
HO
OHC
N
N
S
N
,


,

,

,

,

,

,

,

,

,

,

,


,
, 
, 
, 
, 
, 
, 
, 
, 
, 
,
, or 
.

Claim 8: A pharmaceutical composition comprising at least one compound according to claim 1, or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, optionally further comprising a pharmaceutically acceptable excipient.